Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 8/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963125 | 0.90 | ALDH1A1 (0.43) | MAOBKMT2AMAOAMEN1CYP3A4 | |
| SCHEMBL24775484 | 0.90 | ALDH1A1 (0.43) | MAOBKMT2AMAOAMEN1CYP3A4 | |
| SCHEMBL25053559 | 0.85 | KDM1A (0.42) | MAOBKMT2AMAOAMEN1CYP3A4 | |
| SCHEMBL25053374 | 0.82 | KDM1A (0.35) | MAOBKMT2AMAOAMEN1CYP3A4 | |
| SCHEMBL25053537 | 0.81 | DRD2 (0.39) | MAOBKMT2AMAOAGAAKDM4E | |
| SCHEMBL4104823 | 0.80 | KDM1A (0.41) | RIPK1KDM1AKDM1B | |
| SCHEMBL25053541 | 0.79 | RIPK1 (0.35) | MAOBKMT2AMAOAGAAKDM4E | |
| SCHEMBL9965914 | 0.75 | ALDH1A1 (0.45) | MAOBKMT2AMAOAMEN1CYP3A4 | |
| SCHEMBL4102035 | 0.74 | CHRNB2 (0.48) | ALDH1A1RIPK1KDM1A | |
| SCHEMBL636743 | 0.74 | MAOB (0.41) | MAOBKMT2AMAOAMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | MAOB 3225/4885KMT2A 1976/4885MAOA 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.